Results 181 to 190 of about 1,796 (202)
Some of the next articles are maybe not open access.

AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program

Clinical Lymphoma Myeloma and Leukemia, 2023
Astghik Voskanyan   +30 more
openaire   +1 more source

Genetic Landscape of BPDCN Arising in CML Remission

Blood, 2022
Masataka Takeshita   +10 more
openaire   +1 more source

POSTER: AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program

Clinical Lymphoma Myeloma and Leukemia, 2023
Astghik Voskanyan   +30 more
openaire   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an orphan malignancy defined by the WHO as affection fewer than 65 per 100,000 people and by the U.S. FDA as affecting less than 200,000 people in the U.S..
Astghik Voskanyan   +42 more
openaire   +1 more source

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2020
Mansour Alfayez, Naveen Pemmaraju
exaly  

BPDCN: die frühe Diagnose ist entscheidend

Schweizerische Ärztezeitung
Werner Kempf   +8 more
openaire   +1 more source

Home - About - Disclaimer - Privacy